Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis

Orphanet Journal of Rare Diseases

Deborah O’Neil¹  Derry Mercer¹  Douglas Fraser-Pitt¹  Nicola Shand¹  Aleksandra Kowalczuk¹  Jennifer Robertson¹  Catherine Rodger¹  Cedric Charrier¹ 

[1] NovaBiotics Ltd, Cruickshank Building, Aberdeen AB21 9TR, Craibstone, UK

关键词: Synergy;    Antibiofilm;    Biofilm;    Antimicrobial;    Antibacterial;    Mucolytic;    Cystic fibrosis;   

Others  :  1149273
DOI  :  10.1186/s13023-014-0189-2

 received in 2014-07-07, accepted in 2014-11-10,  发布年份 2014

【 摘 要 】

Background

There remains a critical need for more effective, safe, long-term treatments for cystic fibrosis (CF). Any successful therapeutic strategy designed to combat the respiratory pathology of this condition must address the altered lung physiology and recurrent, complex, polymicrobial infections and biofilms that affect the CF pulmonary tract. Cysteamine is a potential solution to these unmet medical needs and is described here for the first time as (Lynovex®) a single therapy with the potential to deliver mucoactive, antibiofilm and antibacterial properties; both in oral and inhaled delivery modes. Cysteamine is already established in clinical practice for an unrelated orphan condition, cystinosis, and is therefore being repurposed (in oral form) for cystic fibrosis from a platform of over twenty years of safety data and clinical experience.

Methods

The antibacterial and antibiofilm attributes of cysteamine were determined against type strain and clinical isolates of CF relevant pathogens using CLSI standard and adapted microbiological methods and a BioFlux microfluidic system. Assays were performed in standard nutrient media conditions, minimal media, to mimic the low metabolic activity of microbes/persister cells in the CF respiratory tract and in artificial sputum medium. In vivo antibacterial activity was determined in acute murine lung infection/cysteamine nebulisation models. The mucolytic potential of cysteamine was assessed against DNA and mucin in vitro by semi-quantitative macro-rheology. In all cases, the ‘gold standard’ therapeutic agents were employed as control/comparator compounds against which the efficacy of cysteamine was compared.

Results

Cysteamine demonstrated at least comparable mucolytic activity to currently available mucoactive agents. Cysteamine was rapidly bactericidal against both metabolically active and persister cells of Pseudomonas aeruginosa and also emerging CF pathogens; its activity was not sensitive to high ionic concentrations characteristic of the CF lung. Cysteamine prevented the formation of, and disrupted established P. aeruginosa biofilms. Cysteamine was synergistic with conventional CF antibiotics; reversing antibiotic resistance/insensitivity in CF bacterial pathogens.

Conclusions

The novel mucolytic-antimicrobial activity of cysteamine (Lynovex®) provides potential for a much needed new therapeutic strategy in cystic fibrosis. The data we present here provides a platform for cysteamine’s continued investigation as a novel treatment for this poorly served orphan disease.

【 授权许可】

   
2014 Charrier et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Plummer A, Wildman M: Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev 2013, 5:CD006682.
• [2]Bhatt JM: Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev 2013, 22:205-216.
• [3]Storey S, Wald G: Novel agents in cystic fibrosis. Nat Rev Drug Discov 2008, 7:555-556.
• [4]Balsamo R, Lanata L, Egan CG: Mucoactive drugs. Eur Respir Rev 2010, 19:127-133.
• [5]Jones AP, Wallis C: Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews. 2010, Issue 3.Art.No.:CD001127. doi:10.1002/14651858.CD001127.pub2.
• [6]Banerjee D, Stableforth D: The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way? Drugs 2000, 60:1053-1064.
• [7]Sorde R, Pahissa A, Rello J: Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis. Infect Drug Resist 2011, 4:31-41.
• [8]Canton R, Morosini MI: Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol Rev 2011, 35:977-991.
• [9]Lyczak JB, Cannon CL, Pier GB: Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002, 15:194-222.
• [10]O’Neil D, Charrier C: A composition comprising an antibiotic and a dispersant or an anti-adhesive agent.PCT/GB2011/001721 2011.
• [11]O’Neil D, Mercer D, Charrier C: Inhibition of Biofilm Organisms.PCT/GB2010/000631 2010.
• [12]Gahl WA, Tietze F, Butler JD, Schulman JD: Cysteamine depletes cystinotic leucocyte granular fractions of cystine by the mechanism of disulphide interchange. Biochem J 1985, 228:545-550.
• [13]Gahl WA, Balog JZ, Kleta R: Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Intern Med 2007, 147:242-250.
• [14]Hoffmann N, Rasmussen TB, Jensen PO, Stub C, Hentzer M, Molin S, Ciofu O, Givskov M, Johansen HK, Hoiby N: Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun 2005, 73:2504-2514.
• [15]O’Neill E, Pozzi C, Houston P, Smyth D, Humphreys H, Robinson DA, O’Gara JP: Association between methicillin susceptibility and biofilm regulation in Staphylococcus aureus isolates from device-related infections. J Clin Microbiol 2007, 45:1379-1388.
• [16]Pearson JP, Ward R, Allen A, Roberts NB, Taylor WH: Mucus degradation by pepsin: comparison of mucolytic activity of human pepsin 1 and pepsin 3: implications in peptic ulceration. Gut 1986, 27:243-248.
• [17]Handra-Luca A, Lamas G, Bertrand JC, Fouret P: MUC1, MUC2, MUC4, and MUC5AC expression in salivary gland mucoepidermoid carcinoma: diagnostic and prognostic implications. Am J Surg Pathol 2005, 29:881-889.
• [18]Book Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Ninth Edition; M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA; 2012.
• [19]Yang Y, Tsifansky MD, Shin S, Lin Q, Yeo Y: Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnol Bioeng 2011, 108:1441-1449.
• [20]Sambrook J, Fritsch EF, Maniatic T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; 1989.
• [21]Burkhart CG, Burkhart CN, Isham N: Synergistic antimicrobial activity by combining an allylamine with benzoyl peroxide with expanded coverage against yeast and bacterial species. Br J Dermatol 2006, 154:341-344.
• [22]Sandberg T, Carlsson J, Ott MK: Mucin coatings suppress neutrophil adhesion to a polymeric model biomaterial. Microsc Res Tech 2007, 70:864-868.
• [23]Alipour M, Suntres ZE, Omri A: Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J Antimicrob Chemother 2009, 64:317-325.
• [24]Voynow JA, Rubin BK: Mucins, mucus, and sputum. Chest 2009, 135:505-512.
• [25]Gaspar MC, Couet W, Olivier JC, Pais AA, Sousa JJ: Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur J Clin Microbiol Infect Dis 2013, 32:1231-1252.
• [26]Performance Standards for Antimicrobial Susceptibility Testing; Twenty Fourth Informational Supplement. CLSI Document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA; 2014.
• [27]English WP, Williams MD: Should aminoglycoside antibiotics be abandoned? Am J Surg 2000, 180:512-515. discussion 515–516
• [28]Fischbach MA: Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol 2011, 14:519-523.
• [29]Stubbings W, Bostock J, Ingham E, Chopra I: Mechanisms of the post-antibiotic effects induced by rifampicin and gentamicin in Escherichia coli. J Antimicrob Chemother 2006, 58:444-448.